Integrated Filing — IndAS



General information about company
Scrip Code 531349
NSE Symbol PANACEABIO
MSEI Symbol NOTLISTED
ISIN INE922B01023
Name of company Panacea Biotec Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 30-May-2025   14:30:00
End date and time of board meeting 30-May-2025   17:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 1325300000 5590900000
Other income 85900000 206600000
Total income 1411200000 5797500000
2 Expenses
(a) Cost of materials consumed 833200000 2140700000
(b) Purchases of stock-in-trade 74500000 76000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -386900000 -221300000
(d) Employee benefit expense 491300000 1730500000
(e) Finance costs 10400000 38800000
(f) Depreciation, depletion and amortisation expense 84200000 348100000
(f) Other Expenses
1 other expenses 582000000 2124100000
Total other expenses 582000000 2124100000
Total expenses 1688700000 6236900000
3 Total profit before exceptional items and tax -277500000 -439400000
4 Exceptional items 277100000 359900000
5 Total profit before tax -400000 -79500000
6 Tax expense
7 Current tax 100000 100000
8 Deferred tax 19400000 7600000
9 Total tax expenses 19500000 7700000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -19900000 -87200000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -19900000 -87200000
17 Other comprehensive income net of taxes 13600000 11100000
18 Total Comprehensive Income for the period -6300000 -76100000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent -18900000 -83700000
Total profit or loss, attributable to non-controlling interests -1000000 -3500000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent -5300000 -72600000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -1000000 -3500000
21 Details of equity share capital
Paid-up equity share capital 61300000 61300000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 8286600000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.31 -1.37
Diluted earnings (loss) per share from continuing operations -0.31 -1.37
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.31 -1.37
Diluted earnings (loss) per share from continuing and discontinued operations -0.31 -1.37
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 5433900000
Capital work-in-progress 935100000
Investment property 158000000
Goodwill 0
Other intangible assets 77200000
Intangible assets under development 345400000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 700000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 60800000
Total non-current financial assets 61500000
Deferred tax assets (net) 0
Other non-current assets 434600000
Total non-current assets 7445700000
2 Current assets
Inventories 2136700000
Current financial asset
Current investments 31500000
Trade receivables, current 725600000
Cash and cash equivalents 821300000
Bank balance other than cash and cash equivalents 248400000
Loans, current 25700000
Other current financial assets 690000000
Total current financial assets 2542500000
Current tax assets (net) 0
Other current assets 772600000
Total current assets 5451800000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 12897500000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 61300000
Other equity 8286600000
Total equity attributable to owners of parent 8347900000
Non controlling interest -41700000
Total equity 8306200000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 222100000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 4600000
Total non-current financial liabilities 226700000
Provisions, non-current 353400000
Deferred tax liabilities (net) 232800000
Deferred government grants, Non-current 0
Other non-current liabilities 108500000
Total non-current liabilities 921400000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 141800000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2115800000
Total Trade payable 2257600000
Other current financial liabilities 93800000
Total current financial liabilities 2351400000
Other current liabilities 954900000
Provisions, current 363500000
Current tax liabilities (Net) 100000
Deferred government grants, Current 0
Total current liabilities 3669900000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 4591300000
Total equity and liabilites 12897500000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Vaccines 679000000 3098400000
2 Formulations 646300000 2492500000
Total Segment Revenue 1325300000 5590900000
Less: Inter segment revenue 0 0
Revenue from operations 1325300000 5590900000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Vaccines -188500000 -165200000
2 Formulations 188100000 85700000
Total Profit before tax -400000 -79500000
i. Finance cost 0 0
ii. Other Unallocable Expenditure net off Unallocable income 0 0
Profit before tax -400000 -79500000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Vaccines 8911900000 8911900000
2 Formulations 3985600000 3985600000
Total Segment Asset 12897500000 12897500000
Un-allocable Assets 0 0
Net Segment Asset 12897500000 12897500000
4 Segment Liabilities
Segment Liabilities
1 Vaccines 3508700000 3508700000
2 Formulations 1082600000 1082600000
Total Segment Liabilities 4591300000 4591300000
Un-allocable Liabilities 0 0
Net Segment Liabilities 4591300000 4591300000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that wil not be reclassified to profit and loss 2600000 -800000
Total Amount of items that will not be reclassified to profit and loss 2600000 -800000
2 Income tax relating to items that will not be reclassified to profit or loss 700000 -200000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be classified to profit and loss 11700000 11700000
Total Amount of items that will be reclassified to profit and loss 11700000 11700000
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 13600000 11100000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -79500000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 38800000
Adjustments for decrease (increase) in inventories -357400000
Adjustments for decrease (increase) in trade receivables, current -158400000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -156400000
Adjustments for decrease (increase) in other non-current assets 286700000
Adjustments for other financial assets, non-current -9900000
Adjustments for other financial assets, current -620500000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 742900000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -65400000
Adjustments for increase (decrease) in other non-current liabilities 250000000
Adjustments for depreciation and amortisation expense 348400000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 5900000
Adjustments for provisions, non-current 75400000
Adjustments for other financial liabilities, current -79200000
Adjustments for other financial liabilities, non-current 200000
Adjustments for unrealised foreign exchange losses gains 7600000
Adjustments for dividend income 0
Adjustments for interest income 77100000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -13300000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 218300000
Net cash flows from (used in) operations 138800000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 9700000
Other inflows (outflows) of cash -402800000
Net cash flows from (used in) operating activities -273700000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 503100000
Proceeds from sales of investment property 5800000
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 77100000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 1070000000
Net cash flows from (used in) investing activities 649800000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 0
Dividends paid 0
Interest paid 26600000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -26600000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 349500000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 100000
Net increase (decrease) in cash and cash equivalents 349600000
Cash and cash equivalents cash flow statement at beginning of period 471700000
Cash and cash equivalents cash flow statement at end of period 821300000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s Suresh Surana & Associates LLP Yes 31-Mar-2028